These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34512890)

  • 21. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conventional drug therapy for inflammatory bowel disease.
    Bryant RV; Brain O; Travis SP
    Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory bowel disease surgery in the biologic era.
    Ferrari L; Krane MK; Fichera A
    World J Gastrointest Surg; 2016 May; 8(5):363-70. PubMed ID: 27231514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K; Chintanaboina J
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today.
    Damas OM; Deshpande AR; Avalos DJ; Abreu MT
    J Crohns Colitis; 2015 Oct; 9(10):928-36. PubMed ID: 26129693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug treatment of chronic inflammatory bowel diseases: current status and prospects].
    Seibold F; Wagner AC; Göke B
    Schweiz Med Wochenschr; 2000 Feb; 130(7):222-32. PubMed ID: 10719713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease.
    Becker HEF; Demers K; Derijks LJJ; Jonkers DMAE; Penders J
    Front Microbiol; 2023; 14():1107976. PubMed ID: 36910207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing pharmacologic management of inflammatory bowel disease.
    Chang S; Hanauer S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):595-607. PubMed ID: 28475384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
    Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
    Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory Bowel Disease and Pancreatitis: A Review.
    Ramos LR; Sachar DB; DiMaio CJ; Colombel JF; Torres J
    J Crohns Colitis; 2016 Jan; 10(1):95-104. PubMed ID: 26351384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE.
    Lima CCG; Queiroz NSF; Sobrado CW; Silva GLR; Nahas SC
    Arq Gastroenterol; 2020; 57(3):323-332. PubMed ID: 33027484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
    Godat S; Fournier N; Safroneeva E; Juillerat P; Nydegger A; Straumann A; Vavricka S; Biedermann L; Greuter T; Fraga M; Abdelrahman K; Hahnloser D; Sauter B; Rogler G; Michetti P; Schoepfer AM;
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):612-620. PubMed ID: 29384798
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.